- Paper Report
- Open Access
Pathologic features associated with nonsentinel lymph node metastasis
- Rodolfo Laucirica1
© Current Science Ltd 2000
- Published: 1 December 2000
- Breast carcinoma
- sentinel lymph node
In the appropriate clinical and mammographic setting, SN mapping and biopsy are currently used for the regional control of metastatic breast cancer. Although there are insufficient data to draw definitive conclusions regarding this form of limited nodal surgery, accurate pathologic assessment of the primary tumor and SNs should provide useful information for adjuvant therapeutic decisions.
To identify pathologic features in positive SNs that predict which patients will have residual nodal disease in the axillary lymph nodes (ALNs).
The study group consisted of 194 consecutive patients who had at least one SN metastasis and underwent complete ALND with subsequent pathologic examination of at least 10 ALNs. Age, gender, method of tumor detection, clinical status of the ALNs, and surgical procedure performed were recorded for each patient. Prognostic findings included tumor size, type, grade, estrogen and progesterone receptor and HER-2/neu status. The presence of peritumoral lymphatic vascular invasion (LVI), the number of positive SNs and the presence of extranodal hilar tissue invasion (HTI) were also assessed. After SN biopsy, all patients underwent partial or complete mastectomies. If the nodes were negative by routine histology, immunohistochemistry (IHC) was employed to rule out metastatic disease.
There was no significant correlation between non-SN metastasis and age, palpable versus non-papable tumor, or palpable versus non-palpable ALNs. Tumor size, histologic grade, and LVI were all found to positively correlate with non-SN status. SN macrometastasis occurred in 52% of the patients and 23% had micrometastatic disease. In 25% of the cases, SN metastases were identified by IHC. Of the 53 patients who had extranodal hilar tissue invasion (HTI) associated with SN metastases, 89% had non-SN metastases. The median number of non-SNs examined was 17. Non-SN metastases were detected in 88 of 194 cases. The tumor status of the non-SNs changed the lymph node staging classification for 9% of the study patients. The status of the non-SNs was positively correlated with the size of the SN metastasis, extranodal HTI, primary tumor size, and peritumoral LVI. SN involvement plus extranodal HTI was strongly associated with non-SN metastases (P= 0.0001), but was present in only 65% of patients with non-SN macrometastases. Of the patients with micrometastatic disease in the SN, 26% had non-SN metastases. In this group, only primary tumor size and peritumoral LVI correlated with non-SN metastasis.
SN mapping and biopsy are currently used in conjunction with lumpectomy to treat and stage patients with invasive breast cancer. Given the fact that only a selected group of nodes are identified for pathologic examination, it is imperative that we identify pathologic features in the lumpectomy specimen and positive SNs that will determine which patients will require a subsequent ALND. Previous reports have shown that the size of the primary tumor and SN metastasis positively correlated with the presence of non-SN metastasis. Based on the findings in this study, other factors that help predict non-SN metastatic disease include the presence of peritumoral LVI and extranodal HTI.